Skip to main content
Top
Published in: International Urology and Nephrology 3/2017

01-03-2017 | Urology - Original Paper

Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma

Authors: Ryo Yamashita, Reiko Watanabe, Ichiro Ito, Hideo Shinsaka, Masafumi Nakamura, Masato Matsuzaki, Masashi Niwakawa

Published in: International Urology and Nephrology | Issue 3/2017

Login to get access

Abstract

Purpose

To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs).

Methods

We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients). We classified UUTUCs into three types: renal pelvic, short-length ureteral, and long-length ureteral cancer; the cutoff for categorizing short- versus long-length ureteral cancer was the median tumor length. Univariate and multivariate analyses with Cox regression methods were performed to calculate hazard ratios (HRs) for BC recurrence using nine clinical covariates, including our new pathologic classification.

Results

The median follow-up period for the survivors was 60 months (range 1–157 months). Of 99 patients, 36 (36%) had BC recurrence; of these 36 patients, 30 (85%) experienced recurrence within 2 years and 17 (47%) had invasive BC (≥pT1). Statistical analyses demonstrated that pathologic tumor type was the major significant risk factor for BC recurrence. Long-length (>5 cm) ureteral cancer had the highest risk of BC recurrence compared to other tumor types (multivariate HR 2.1; 95% confidence interval 1.03–4.2).

Conclusions

Our simple classification system based on the tumor’s pathologic appearance is useful for predicting BC recurrence. Patients with long-length ureteral cancer have a high risk of BC recurrence.
Literature
5.
go back to reference Seisen T, Granger B, Colin P, Leon P, Utard G, Renard-Penna R, Comperat E, Mozer P, Cussenot O, Shariat SF, Roupret M (2015) A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 67:1122–1133. doi:10.1016/j.eururo.2014.11.035 CrossRefPubMed Seisen T, Granger B, Colin P, Leon P, Utard G, Renard-Penna R, Comperat E, Mozer P, Cussenot O, Shariat SF, Roupret M (2015) A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 67:1122–1133. doi:10.​1016/​j.​eururo.​2014.​11.​035 CrossRefPubMed
7.
go back to reference Green LF, Page DL, Fleming ID, Fitz AG, Balch CM, Haller DG, Morrow M (2002) American joint committee on cancer (AJCC) cancer staging manual, 6th edn. Springer, New YorkCrossRef Green LF, Page DL, Fleming ID, Fitz AG, Balch CM, Haller DG, Morrow M (2002) American joint committee on cancer (AJCC) cancer staging manual, 6th edn. Springer, New YorkCrossRef
8.
go back to reference Mostfi FK, Davis CJ, Sesterhenn IA (1999) International histological classification of tumours: histological typing of urinary bladder tumours. Springer, BerlinCrossRef Mostfi FK, Davis CJ, Sesterhenn IA (1999) International histological classification of tumours: histological typing of urinary bladder tumours. Springer, BerlinCrossRef
9.
go back to reference O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of Oncology (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60:703–710. doi:10.1016/j.eururo.2011.05.064 CrossRefPubMed O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of Oncology (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60:703–710. doi:10.​1016/​j.​eururo.​2011.​05.​064 CrossRefPubMed
10.
go back to reference Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O (1993) Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342:1087–1088CrossRefPubMed Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O (1993) Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342:1087–1088CrossRefPubMed
12.
go back to reference Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y (2013) Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 31:1422–1427. doi:10.1200/JCO.2012.45.2128 CrossRefPubMed Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y (2013) Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 31:1422–1427. doi:10.​1200/​JCO.​2012.​45.​2128 CrossRefPubMed
13.
go back to reference Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Roupret M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, Shariat SF, Collaboration UTUC (2014) Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 65:650–658. doi:10.1016/j.eururo.2013.09.003 CrossRefPubMed Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Roupret M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, Shariat SF, Collaboration UTUC (2014) Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 65:650–658. doi:10.​1016/​j.​eururo.​2013.​09.​003 CrossRefPubMed
14.
go back to reference Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, Shariat SF (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253. doi:10.1016/j.eururo.2011.09.017 CrossRefPubMed Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, Shariat SF (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253. doi:10.​1016/​j.​eururo.​2011.​09.​017 CrossRefPubMed
15.
go back to reference Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F, Hoarau N, Adam E, Azemar MD, Bensadoun H, Cormier L, Cussenot O, Houlgatte A, Karsenty G, Bruyere F, Maurin C, Nouhaud FX, Phe V, Polguer T, Roumiguie M, Ruffion A, Roupret M, French Collaborative National Database on UUT-UC (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265. doi:10.1016/j.eururo.2011.05.049 CrossRefPubMed Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F, Hoarau N, Adam E, Azemar MD, Bensadoun H, Cormier L, Cussenot O, Houlgatte A, Karsenty G, Bruyere F, Maurin C, Nouhaud FX, Phe V, Polguer T, Roumiguie M, Ruffion A, Roupret M, French Collaborative National Database on UUT-UC (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265. doi:10.​1016/​j.​eururo.​2011.​05.​049 CrossRefPubMed
16.
go back to reference Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen N, Fairey A, Kapoor A, Black P, Lacombe L, Tanguay S, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Izawa JI (2013) Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urol Oncol 31:1161–1165. doi:10.1016/j.urolonc.2011.12.004 CrossRefPubMed Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen N, Fairey A, Kapoor A, Black P, Lacombe L, Tanguay S, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Izawa JI (2013) Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urol Oncol 31:1161–1165. doi:10.​1016/​j.​urolonc.​2011.​12.​004 CrossRefPubMed
17.
go back to reference Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ, Fritsche HM, El-Hakim A, Trishcler S, Martinez-Salamanca JI, Seitz C, Ficarra V, Zattoni F, Karakiewicz PI, Kassouf W (2012) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13. doi:10.1111/j.1464-410X.2011.10792.x CrossRefPubMed Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ, Fritsche HM, El-Hakim A, Trishcler S, Martinez-Salamanca JI, Seitz C, Ficarra V, Zattoni F, Karakiewicz PI, Kassouf W (2012) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13. doi:10.​1111/​j.​1464-410X.​2011.​10792.​x CrossRefPubMed
Metadata
Title
Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma
Authors
Ryo Yamashita
Reiko Watanabe
Ichiro Ito
Hideo Shinsaka
Masafumi Nakamura
Masato Matsuzaki
Masashi Niwakawa
Publication date
01-03-2017
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1510-5

Other articles of this Issue 3/2017

International Urology and Nephrology 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.